Pacific Biosciences Of California (PACB) Net Equity Issued and Repurchased (2010 - 2023)

Pacific Biosciences Of California's Net Equity Issued and Repurchased history runs 13 years deep, the most recent figure standing at $189.2 million for Q1 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $189.2 million in Q1 2023; TTM through Dec 2023 was $189.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $189.2 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased improved to $189.2 million in Q1 2023 per PACB's latest filing, from $1.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $300.0 million in Q3 2021 and bottomed at $131000.0 in Q4 2019.
• The 4-year median for Net Equity Issued and Repurchased is $3.0 million (2021), against an average of $43.9 million.
• Across the five-year window, Net Equity Issued and Repurchased sank 97.61% in 2019 and soared 24469.47% in 2020, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $131000.0 in 2019, then surged by 24469.47% to $32.2 million in 2020, then plunged by 94.76% to $1.7 million in 2021, then surged by 11128.49% to $189.2 million in 2023.
• Per Business Quant, the three latest PACB Net Equity Issued and Repurchased figures stand at $189.2 million (Q1 2023), $1.7 million (Q4 2021), and $300.0 million (Q3 2021).